Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum

Next Previous
X
Search
Trial Profile

Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abacavir (Primary) ; Atazanavir (Primary) ; Atazanavir/cobicistat (Primary) ; Cobicistat (Primary) ; Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Darunavir (Primary) ; Didanosine (Primary) ; Dolutegravir (Primary) ; Efavirenz (Primary) ; Elvitegravir (Primary) ; Emtricitabine (Primary) ; Emtricitabine/rilpivirine/tenofovir alafenamide (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Fosamprenavir (Primary) ; Indinavir (Primary) ; Lopinavir/ritonavir (Primary) ; Maraviroc (Primary) ; Nelfinavir (Primary) ; Nevirapine (Primary) ; Ritonavir (Primary) ; Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Amikacin; Aminosalicylic acid; Bedaquiline; Capreomycin; Clofazimine; Cycloserine; Delamanid; Ethambutol; Ethinylestradiol; Ethionamide; Etonogestrel; Etravirine; Isoniazid; Kanamycin; Levofloxacin; Linezolid; Moxifloxacin; Ofloxacin; Pretomanid; Protionamide; Pyrazinamide; Raltegravir; Rifampicin; Rilpivirine; Terizidone; Tipranavir; Zidovudine
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Acronyms IMPAACT

    • Most Recent Events

    • 12 Feb 2022 Results (n=29) assessing pharmacokinetic, safety, and birth outcomes with TAF 25 mg with a boosted protease inhibitor (PI) in pregnant women living with HIV (PWLH) published in the JAIDS
    • 02 Nov 2021 Results (N=11) of an analysis assessing evaluate the pharmacokinetics and safety of atazanavir and cobicistat (FDC) in pregnant women with HIV-1 published in the JAIDS
    • 15 Aug 2021 Results of an analysis assessing the etonogestrel/antiretroviral therapy drug-drug interactions, and the effects of etonogestrel on ritonavir-boosted-atazanavir, ritonavir-boosted-lopinavir, and efavirenz pharmacokinetics published in the Contraception
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top